Swiss Life Group

ZWEI Wealth Experts is a wealth management firm located in Zurich, Switzerland, established in 2014. The firm aims to create a wealth management ecosystem that prioritizes transparency and control for investors. By functioning as an independent advisor, ZWEI Wealth provides clients with personalized investment strategies, ensuring that their assets are managed by a dedicated executive management team. This approach allows the firm to cater to the specific needs of its clients, fostering trust and clarity in the wealth management process.

Upmin is an online platform that serves as a digital property manager, designed to streamline real estate management for owners and landlords. By automating various processes, Upmin significantly reduces the manual labor typically associated with property management, leading to time and cost savings. The platform offers a comprehensive suite of services, including accounting, utility bill management, deposit management, rent collection, tenant and property management, contract management, and maintenance. Additionally, Upmin provides an optional rental package that assists clients in tenant acquisition, encompassing advertising, marketing, property viewings, and tenant handover. This all-inclusive approach allows property owners to efficiently manage their assets with minimal stress.

PriceHubble is a Swiss B2B proptech company that specializes in creating digital solutions for the real estate sector, focusing on property valuations and market insights. By utilizing big data and advanced analytics, PriceHubble offers a suite of products that enhances transparency in the real estate market. These solutions provide clients, including banks, asset managers, developers, property managers, and real estate agents, with accurate, data-driven insights such as valuations, market analyses, and value forecasts. The company's platform employs proprietary machine learning algorithms to improve valuation models and assess the impact of urban developments, thereby supporting informed decision-making. PriceHubble operates in nine countries, including Switzerland, France, and Germany, and has a workforce of over 130 employees globally.

Zenhomes provides a one-stop shop for private landlords and property managers. The company's digital platform simplifies property and tenant management.

Vermietet.de is a Berlin-based company founded by a group of entrepreneurs and investors with the aim of simplifying real estate ownership. Recognizing the complexities involved in property management, the company has developed a property management platform designed to facilitate secure and efficient management for property owners. This platform assists landlords with various administrative tasks, including document creation, property maintenance, tenant search, and communication. By enabling transparent property valuation, utility cost calculation, and efficient monthly rental payment checks, Vermietet.de seeks to enhance the experience of property ownership and management.

Fincentrum is a leading financial advisory consultancy in the Czech Republic, recognized for its commitment to high-quality advisory services and client representation. The company assists individuals and businesses in navigating the complexities of finance by offering access to a wide range of financial institutions and products, including insurance, loans, investments, savings, and pensions. By prioritizing the interests of its clients, Fincentrum provides tailored solutions to address diverse financial needs, ensuring that both individuals and corporations receive comprehensive support in their financial decision-making.

LaFinBox is a free and secure app that manages your money in all your financial institutions. LaFinBox was created in 2015 on the initiative of Swiss Life, a leading player in the insurance and wealth management market. Founded in 1857, the group is one of Europe's leading providers of comprehensive solutions in global pensions and finance. Through a comprehensive approach, Swiss Life advisers support individuals and businesses in a variety of areas: life insurance, private banking, financial management, health, welfare, and property damage. They offer their customers a wide range of personalized solutions, adapted to the needs and evolutions of each, in the long term. LaFinBox centralizes all financial and investment support: current accounts, bank cards, loans, passbooks, employee savings, life insurance, PEA, mortgage.

PriceHubble is a Swiss B2B proptech company that specializes in creating digital solutions for the real estate sector, focusing on property valuations and market insights. By utilizing big data and advanced analytics, PriceHubble offers a suite of products that enhances transparency in the real estate market. These solutions provide clients, including banks, asset managers, developers, property managers, and real estate agents, with accurate, data-driven insights such as valuations, market analyses, and value forecasts. The company's platform employs proprietary machine learning algorithms to improve valuation models and assess the impact of urban developments, thereby supporting informed decision-making. PriceHubble operates in nine countries, including Switzerland, France, and Germany, and has a workforce of over 130 employees globally.

Bexio is a Swiss-based company that helps small businesses with cloud-based business and accounting software to grow their businesses. It develops and sells accounting software for small and medium companies. Bexio was founded in 2013 and is based in Rapperswil, Zurich.

Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002 and headquartered in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, focusing on nuclear receptors to address various disease areas, including liver diseases, intestinal diseases, and cancer. Current research includes developing RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. Phenex is dedicated to not only creating therapeutics for established targets but also identifying novel molecular mechanisms, which has led to the development of proprietary therapeutic small molecules. The company operates within the Biotech Cluster Rhine-Neckar, leveraging its expertise in biology and chemistry to advance innovative treatment options.

AWD Holding AG, along with its subsidiaries, provides individual financial advice and planning services in Europe. It focuses on provision of hedge fund and old-age pension products, and long-term growth of assets. The company provides retirement provision services; and private asset accumulation and asset retirement planning services for private customers. It serves customers in Germany, Austria, Czech Republic, Hungary, Poland, Slovakia, Great Britain, and Switzerland. AWD Holding AG was formerly known as Allgemeiner Wirtschaftsdienst. The company was founded in 1988 and is based in Hanover, Germany. It has independent representative offices in Germany, the United Kingdom, Austria, Switzerland, and Central and Eastern Europe. AWD Holding AG operates as a subsidiary of Swiss Life Deutschland Holding GmbH.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Iolon, Inc. is a privately held company specializing in optical networking components. It develops high-performance tunable devices designed for advanced fiber optic networks. The company's initial offering is a high-powered, external cavity tunable laser source suitable for high bit rate and long-haul applications. Iolon plans to expand its product range to include tunable filters, optical switches, polarization controllers, spectral monitors, and universal transponders. The technology platform employed by Iolon supports advanced automation for high-volume manufacturing and is based on patented micro-optics, MEMS, and sophisticated servo control technologies. Their products are utilized by customers in various applications, including the transmission, monitoring, and reception of optical signals, as well as in testing and measurement equipment.

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders in the United States and internationally. The company’s primary product, Ampyra (dalfampridine), is an oral medication approved to enhance walking in patients with multiple sclerosis. Additionally, Acorda markets Inbrija, an inhalation powder for the treatment of OFF periods in individuals with Parkinson's disease. The company's pipeline includes rHIgM22, which has completed Phase I trials for multiple sclerosis, and Cimaglermin alfa, currently in Phase Ib trials for heart failure. Acorda has established a collaboration with Biogen for the development and commercialization of Ampyra. Founded in 1995 and based in Ardsley, New York, Acorda Therapeutics aims to improve the quality of life for those affected by neurological conditions.